Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Altered gene expression of hydrogen sulfide-producing enzymes in the liver and muscles tissues of hyperthyroid rats.

Jeddi S, Gholami H, Gheibi S, Kashfi K, Ghasemi A.

J Cell Physiol. 2019 Aug;234(10):17937-17945. doi: 10.1002/jcp.28426. Epub 2019 Mar 1.

PMID:
30825200
2.

Effects of Hydrogen Sulfide on Carbohydrate Metabolism in Obese Type 2 Diabetic Rats.

Gheibi S, Jeddi S, Kashfi K, Ghasemi A.

Molecules. 2019 Jan 6;24(1). pii: E190. doi: 10.3390/molecules24010190.

3.

Development of new generation of vaccines for Brucella abortus.

Gheibi A, Khanahmad H, Kashfi K, Sarmadi M, Khorramizadeh MR.

Heliyon. 2018 Dec 26;4(12):e01079. doi: 10.1016/j.heliyon.2018.e01079. eCollection 2018 Dec. Review.

4.

Effects of long-term oral nitrate administration on adiposity in normal adult female rats.

Bakhtiarzadeh F, Siavoshi F, Gheibi S, Kashfi K, Samadi R, Jeddi S, Ghasemi A.

Life Sci. 2018 Oct 1;210:76-85. doi: 10.1016/j.lfs.2018.08.032. Epub 2018 Aug 15.

PMID:
30118772
5.

The role of hydrogen sulfide in health and disease.

Kashfi K.

Biochem Pharmacol. 2018 Mar;149:1-4. doi: 10.1016/j.bcp.2018.02.030. Epub 2018 Feb 28. No abstract available.

PMID:
29501583
6.

The dichotomous role of H2S in cancer cell biology? Déjà vu all over again.

Kashfi K.

Biochem Pharmacol. 2018 Mar;149:205-223. doi: 10.1016/j.bcp.2018.01.042. Epub 2018 Feb 14. Review.

7.

Regulation of vascular tone homeostasis by NO and H2S: Implications in hypertension.

Gheibi S, Jeddi S, Kashfi K, Ghasemi A.

Biochem Pharmacol. 2018 Mar;149:42-59. doi: 10.1016/j.bcp.2018.01.017. Epub 2018 Jan 9. Review.

8.

A practical guide for induction of type-2 diabetes in rat: Incorporating a high-fat diet and streptozotocin.

Gheibi S, Kashfi K, Ghasemi A.

Biomed Pharmacother. 2017 Nov;95:605-613. doi: 10.1016/j.biopha.2017.08.098. Epub 2017 Sep 4. Review.

PMID:
28881291
9.

Hyper-brain connectivity in binge drinking college students: a diffusion tensor imaging study.

Kashfi K, Al-Khalil K, Hou J, Fang D, Anderson R, Rajmohan R, Syapin P, O'Boyle MW.

Neurocase. 2017 Jun - Aug;23(3-4):179-186. doi: 10.1080/13554794.2017.1347264. Epub 2017 Jul 10.

PMID:
28691585
10.

Mirror neuron activation of musicians and non-musicians in response to motion captured piano performances.

Hou J, Rajmohan R, Fang D, Kashfi K, Al-Khalil K, Yang J, Westney W, Grund CM, O'Boyle MW.

Brain Cogn. 2017 Jul;115:47-55. doi: 10.1016/j.bandc.2017.04.001. Epub 2017 May 2.

PMID:
28460215
11.

Gastrointestinal safety, chemotherapeutic potential, and classic pharmacological profile of NOSH-naproxen (AVT-219) a dual NO- and H2S-releasing hybrid.

Chattopadhyay M, Kodela R, Duvalsaint PL, Kashfi K.

Pharmacol Res Perspect. 2016 Mar 4;4(2):e00224. doi: 10.1002/prp2.224. eCollection 2016 Apr.

12.

NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid has enhanced chemo-preventive properties compared to aspirin, is gastrointestinal safe with all the classic therapeutic indications.

Kodela R, Chattopadhyay M, Velázquez-Martínez CA, Kashfi K.

Biochem Pharmacol. 2015 Dec 15;98(4):564-72. doi: 10.1016/j.bcp.2015.09.014. Epub 2015 Sep 21.

13.

Hydrogen sulfide-releasing naproxen suppresses colon cancer cell growth and inhibits NF-κB signaling.

Kodela R, Nath N, Chattopadhyay M, Nesbitt DE, Velázquez-Martínez CA, Kashfi K.

Drug Des Devel Ther. 2015 Aug 24;9:4873-82. doi: 10.2147/DDDT.S91116. eCollection 2015.

14.

The dual role of iNOS in cancer.

Vannini F, Kashfi K, Nath N.

Redox Biol. 2015 Dec;6:334-343. doi: 10.1016/j.redox.2015.08.009. Epub 2015 Aug 24. Review.

15.

Synthesis and anti-cancer potential of the positional isomers of NOSH-aspirin (NBS-1120) a dual nitric oxide and hydrogen sulfide releasing hybrid.

Vannini F, MacKessack-Leitch AC, Eschbach EK, Chattopadhyay M, Kodela R, Kashfi K.

Bioorg Med Chem Lett. 2015 Oct 15;25(20):4677-82. doi: 10.1016/j.bmcl.2015.08.023. Epub 2015 Aug 14.

16.

Positional isomerism markedly affects the growth inhibition of colon cancer cells by NOSH-aspirin: COX inhibition and modeling.

Vannini F, Chattopadhyay M, Kodela R, Rao PPN, Kashfi K.

Redox Biol. 2015 Dec;6:318-325. doi: 10.1016/j.redox.2015.08.014. Epub 2015 Aug 20.

18.

NOSH-aspirin (NBS-1120), a dual nitric oxide and hydrogen sulfide-releasing hybrid, reduces inflammatory pain.

Fonseca MD, Cunha FQ, Kashfi K, Cunha TM.

Pharmacol Res Perspect. 2015 Jun;3(3):e00133. doi: 10.1002/prp2.133. Epub 2015 May 8.

19.

NOSH-Aspirin Inhibits Colon Cancer Cell Growth: Effects Of Positional Isomerism.

Vannini F, Kodela R, Chattopadhyay M, Kashfi K.

Redox Biol. 2015 Aug;5:421. doi: 10.1016/j.redox.2015.09.033. Epub 2015 Dec 30.

20.

Utility Of Nitric Oxide And Hydrogen Sulfide-Releasing Chimeras As Anticancer Agents.

Kashfi K.

Redox Biol. 2015 Aug;5:420. doi: 10.1016/j.redox.2015.09.030. Epub 2015 Dec 30.

21.

Nitric Oxide-Releasing Aspirin Suppresses NF-κB Signaling in Estrogen Receptor Negative Breast Cancer Cells in Vitro and in Vivo.

Nath N, Chattopadhyay M, Rodes DB, Nazarenko A, Kodela R, Kashfi K.

Molecules. 2015 Jul 9;20(7):12481-99. doi: 10.3390/molecules200712481.

24.

Hydrogen sulfide-releasing aspirin inhibits the growth of leukemic Jurkat cells and modulates β-catenin expression.

Chattopadhyay M, Nath N, Kodela R, Sobocki T, Metkar S, Gan ZY, Kashfi K.

Leuk Res. 2013 Oct;37(10):1302-8. doi: 10.1016/j.leukres.2013.07.004. Epub 2013 Jul 26.

25.

Flurbiprofen benzyl nitrate (NBS-242) inhibits the growth of A-431 human epidermoid carcinoma cells and targets β-catenin.

Nath N, Liu X, Jacobs L, Kashfi K.

Drug Des Devel Ther. 2013 May 6;7:389-96. doi: 10.2147/DDDT.S43771. Print 2013.

26.

Anti-cancer activity of new designer hydrogen sulfide-donating hybrids.

Kashfi K.

Antioxid Redox Signal. 2014 Feb 10;20(5):831-46. doi: 10.1089/ars.2013.5308. Epub 2013 Jun 7. Review.

27.

Positional isomers of aspirin are equally potent in inhibiting colon cancer cell growth: differences in mode of cyclooxygenase inhibition.

Kodela R, Chattopadhyay M, Goswami S, Gan ZY, Rao PP, Nia KV, Velázquez-Martínez CA, Kashfi K.

J Pharmacol Exp Ther. 2013 Apr;345(1):85-94. doi: 10.1124/jpet.112.201970. Epub 2013 Jan 24.

28.

Dysfunctional cell signaling dynamics in oncology: diagnostic, prognostic and treatment opportunities.

Kashfi K.

Biochem Pharmacol. 2013 Mar 1;85(5):595-596. doi: 10.1016/j.bcp.2012.12.020. Epub 2013 Jan 3. No abstract available.

PMID:
23291241
29.

Biology and therapeutic potential of hydrogen sulfide and hydrogen sulfide-releasing chimeras.

Kashfi K, Olson KR.

Biochem Pharmacol. 2013 Mar 1;85(5):689-703. doi: 10.1016/j.bcp.2012.10.019. Epub 2012 Oct 24. Review.

30.

NOSH-Aspirin: A Novel Nitric Oxide-Hydrogen Sulfide-Releasing Hybrid: A New Class of Anti-inflammatory Pharmaceuticals.

Kodela R, Chattopadhyay M, Kashfi K.

ACS Med Chem Lett. 2012 Mar 8;3(3):257-262. Epub 2012 Jan 28.

31.

NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model.

Chattopadhyay M, Kodela R, Olson KR, Kashfi K.

Biochem Biophys Res Commun. 2012 Mar 16;419(3):523-8. doi: 10.1016/j.bbrc.2012.02.051. Epub 2012 Feb 16.

PMID:
22366248
32.

Hydrogen sulfide-releasing NSAIDs inhibit the growth of human cancer cells: a general property and evidence of a tissue type-independent effect.

Chattopadhyay M, Kodela R, Nath N, Dastagirzada YM, Velázquez-Martínez CA, Boring D, Kashfi K.

Biochem Pharmacol. 2012 Mar 15;83(6):715-22. doi: 10.1016/j.bcp.2011.12.018. Epub 2011 Dec 26.

PMID:
22222427
33.

Hydrogen sulfide-releasing aspirin suppresses NF-κB signaling in estrogen receptor negative breast cancer cells in vitro and in vivo.

Chattopadhyay M, Kodela R, Nath N, Barsegian A, Boring D, Kashfi K.

Biochem Pharmacol. 2012 Mar 15;83(6):723-32. doi: 10.1016/j.bcp.2011.12.019. Epub 2011 Dec 24.

PMID:
22209867
34.

Hydrogen sulfide-releasing aspirin modulates xenobiotic metabolizing enzymes in vitro and in vivo.

Chattopadhyay M, Kodela R, Nath N, Street CR, Velázquez-Martínez CA, Boring D, Kashfi K.

Biochem Pharmacol. 2012 Mar 15;83(6):733-40. doi: 10.1016/j.bcp.2011.12.020. Epub 2011 Dec 24.

PMID:
22209714
35.
36.

Nitric oxide release is not required to decrease the ulcerogenic profile of nonsteroidal anti-inflammatory drugs.

Jain S, Tran S, El Gendy MA, Kashfi K, Jurasz P, Velázquez-Martínez CA.

J Med Chem. 2012 Jan 26;55(2):688-96. doi: 10.1021/jm200973j. Epub 2012 Jan 10.

PMID:
22148253
37.

Synthesis and biological activity of acetyl-protected hydroxybenzyl diethyl phosphates (EHBP) as potential chemotherapeutic agents.

Kodela R, Chattopadhyay M, Nath N, Cieciura LZ, Pospishill L, Boring D, Crowell JA, Kashfi K.

Bioorg Med Chem Lett. 2011 Dec 1;21(23):7146-50. doi: 10.1016/j.bmcl.2011.09.075. Epub 2011 Sep 22.

PMID:
22001089
38.

Membrane microenvironment regulation of carnitine palmitoyltranferases I and II.

Kashfi K, Mynatt RL, Park EA, Cook GA.

Biochem Soc Trans. 2011 Jun;39(3):833-7. doi: 10.1042/BST0390833.

PMID:
21599656
39.

JS-K, a nitric oxide-releasing prodrug, modulates ß-catenin/TCF signaling in leukemic Jurkat cells: evidence of an S-nitrosylated mechanism.

Nath N, Chattopadhyay M, Pospishil L, Cieciura LZ, Goswami S, Kodela R, Saavedra JE, Keefer LK, Kashfi K.

Biochem Pharmacol. 2010 Dec 1;80(11):1641-9. doi: 10.1016/j.bcp.2010.08.011. Epub 2010 Aug 24.

PMID:
20797387
40.

Comparison between 3-Nitrooxyphenyl acetylsalicylate (NO-ASA) and O2-(acetylsalicyloxymethyl)-1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (NONO-ASA) as safe anti-inflammatory, analgesic, antipyretic, antioxidant prodrugs.

Chattopadhyay M, Velazquez CA, Pruski A, Nia KV, Abdellatif KR, Keefer LK, Kashfi K.

J Pharmacol Exp Ther. 2010 Nov;335(2):443-50. doi: 10.1124/jpet.110.171017. Epub 2010 Aug 2. Erratum in: J Pharmacol Exp Ther. 2010 Dec;335(3):861.

41.

NO-releasing NSAIDs suppress NF-κB signaling in vitro and in vivo through S-nitrosylation.

Chattopadhyay M, Goswami S, Rodes DB, Kodela R, Velazquez CA, Boring D, Crowell JA, Kashfi K.

Cancer Lett. 2010 Dec 8;298(2):204-11. doi: 10.1016/j.canlet.2010.07.006. Epub 2010 Jul 31.

PMID:
20674154
42.

Modulation of stress genes expression profile by nitric oxide-releasing aspirin in Jurkat T leukemia cells.

Nath N, Chattopadhyay M, Kodela R, Tian S, Vlismas P, Boring D, Crowell JA, Kashfi K.

Biochem Pharmacol. 2010 Jun 15;79(12):1759-71. doi: 10.1016/j.bcp.2010.02.011. Epub 2010 Feb 24.

PMID:
20188076
43.

Nitro-aspirin inhibits MCF-7 breast cancer cell growth: effects on COX-2 expression and Wnt/beta-catenin/TCF-4 signaling.

Nath N, Vassell R, Chattopadhyay M, Kogan M, Kashfi K.

Biochem Pharmacol. 2009 Nov 15;78(10):1298-304. doi: 10.1016/j.bcp.2009.06.104. Epub 2009 Jul 2.

PMID:
19576865
44.

Anti-inflammatory agents as cancer therapeutics.

Kashfi K.

Adv Pharmacol. 2009;57:31-89. doi: 10.1016/S1054-3589(08)57002-5. Epub 2009 Nov 27. Review.

PMID:
20230759
45.

The mechanism of action of nitric oxide-donating aspirin.

Kashfi K, Rigas B.

Biochem Biophys Res Commun. 2007 Jul 13;358(4):1096-101. Epub 2007 May 15.

PMID:
17512900
46.

Comparison of (+)- and (-)-hemipalmitoylcarnitinium as inhibitors of hepatic mitochondrial carnitine palmitoyltransferases in diabetic rats.

Savle PS, Neptune NE, Yang Y, Rouden JH, Kite BL, Sugandhi EW, Macri RV, Kashfi K, Gandour RD.

Med Chem. 2005 Sep;1(5):445-53.

PMID:
16787328
47.

Nitric oxide-donating aspirin prevents pancreatic cancer in a hamster tumor model.

Ouyang N, Williams JL, Tsioulias GJ, Gao J, Iatropoulos MJ, Kopelovich L, Kashfi K, Rigas B.

Cancer Res. 2006 Apr 15;66(8):4503-11.

48.

NO-donating aspirin induces phase II enzymes in vitro and in vivo.

Gao J, Kashfi K, Liu X, Rigas B.

Carcinogenesis. 2006 Apr;27(4):803-10. Epub 2005 Nov 2.

PMID:
16267095
49.

NO-donating aspirin inhibits both the expression and catalytic activity of inducible nitric oxide synthase in HT-29 human colon cancer cells.

Spiegel A, Hundley TR, Chen J, Gao J, Ouyang N, Liu X, Go MF, Tsioulias GJ, Kashfi K, Rigas B.

Biochem Pharmacol. 2005 Oct 1;70(7):993-1000.

PMID:
16105666
50.

Is COX-2 a 'collateral' target in cancer prevention?

Kashfi K, Rigas B.

Biochem Soc Trans. 2005 Aug;33(Pt 4):724-7. Review.

PMID:
16042585

Supplemental Content

Loading ...
Support Center